Similar articles for PMID: 22258390

Year	Number of Results
1997	1
2001	2
2003	6
2004	11
2005	5
2006	8
2007	16
2008	13
2009	8
2010	5
2011	6
2012	6
2013	8
2014	6
2015	2
2016	1
2017	2
2018	1
2019	2
2022	1
2024	0

1

Development of resistance to biologic therapies with reference to IFN-β.

Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI. Farrell RA, et al. Rheumatology (Oxford). 2012 Apr;51(4):590-9. doi: 10.1093/rheumatology/ker445. Epub 2012 Jan 18. Rheumatology (Oxford). 2012. PMID: 22258390 Review.

2

Neutralizing antibodies to interferon.

Noronha A. Noronha A. Neurology. 2007 Jun 12;68(24 Suppl 4):S16-22. doi: 10.1212/01.wnl.0000277705.63813.84. Neurology. 2007. PMID: 17562846 Review.

3

Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.

Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B. Weber F, et al. Pharmacogenomics J. 2012 Jun;12(3):238-45. doi: 10.1038/tpj.2011.14. Epub 2011 Apr 19. Pharmacogenomics J. 2012. PMID: 21502966

4

Predictive markers for response to interferon therapy in patients with multiple sclerosis.

Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A. Malucchi S, et al. Neurology. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b. Epub 2008 Feb 13. Neurology. 2008. PMID: 18272865

5

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.

Pachner AR, Cadavid D, Wolansky L, Skurnick J. Pachner AR, et al. Neurology. 2009 Nov 3;73(18):1485-92. doi: 10.1212/WNL.0b013e3181bf9919. Neurology. 2009. PMID: 19884576 Clinical Trial.

6

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.

Ravnborg M, Bendtzen K, Christensen O, Jensen PE, Hesse D, Tovey MG, Sørensen PS. Ravnborg M, et al. Mult Scler. 2009 Mar;15(3):323-8. doi: 10.1177/1352458508099476. Epub 2008 Nov 21. Mult Scler. 2009. PMID: 19028832 Clinical Trial.

7

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.

Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F. Bertolotto A, et al. J Immunol Methods. 2007 Apr 10;321(1-2):19-31. doi: 10.1016/j.jim.2006.12.012. Epub 2007 Feb 20. J Immunol Methods. 2007. PMID: 17335844

8

An association between autoreactive antibodies and anti-interferon-beta antibodies in multiple sclerosis.

Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M. Garg N, et al. Mult Scler. 2007 Aug;13(7):895-9. doi: 10.1177/1352458507076968. Epub 2007 Apr 27. Mult Scler. 2007. PMID: 17468449

9

Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.

Farrell RA, Giovannoni G. Farrell RA, et al. Mult Scler. 2007 Jun;13(5):567-77. doi: 10.1177/1352458506073522. Epub 2007 Feb 16. Mult Scler. 2007. PMID: 17548434 Review.

10

Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.

Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B; RNF Study Group. Giovannoni G, et al. Clin Ther. 2007 Jun;29(6):1128-45. doi: 10.1016/j.clinthera.2007.06.002. Clin Ther. 2007. PMID: 17692727 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year